A retrospective comparison of the emergent use of fixed-dose four-factor prothrombin complex versus weight-based dosing for intracranial hemorrhage assessing medication delivery time and cost.
Gordon M Riha, Michael S Englehart, Karin Z Walton, Megan E Saunders, Benjamin T Carter, Simon J Thompson
{"title":"A retrospective comparison of the emergent use of fixed-dose four-factor prothrombin complex versus weight-based dosing for intracranial hemorrhage assessing medication delivery time and cost.","authors":"Gordon M Riha, Michael S Englehart, Karin Z Walton, Megan E Saunders, Benjamin T Carter, Simon J Thompson","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The goal of this study was to evaluate a low fixed-dose versus weight-based dosing strategy for four-factor prothrombin complex (4F-PCC) time to administration in intracranial hemorrhage (ICH) patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted at a single rural Tertiary referral center in patients ≥18 years old on warfarin with ICH who received 4F-PCC. Continuous variables were summarized using mean (±95% CI) and compared using two-tailed tests; <i>p</i> values ≤0.05 were considered statistically significant.</p><p><strong>Results: </strong>A total of 46 ICH patients were reversed using 4F-PCC (Fixed, n = 27 and Weight, n = 19). Baseline characteristics were equivalent. Total units of 4F-PCC (mean dose units 2525.1 versus 1623.3) and dose per kg were significantly reduced in the fixed-dose group. Total time from order to delivery was significantly reduced with the fixed-dose strategy (mean time 43.0 versus 29.0 minutes). Hospital length of stay (LOS), intensive care unit LOS, and mortality were equivalent with a similar mechanism. International Normalized Ratio (INR) reversal success (≤1.5) and total INR change was comparable with no difference in adverse thromboses between groups.</p><p><strong>Conclusions: </strong>A fixed-dosed strategy reduced time to 4F-PCC administration for warfarin reversal in ICH, as compared to a weight-based strategy; with no increase in LOS, mortality, or need for additional dosing. This also resulted in significant cost savings.</p>","PeriodicalId":14352,"journal":{"name":"International journal of physiology, pathophysiology and pharmacology","volume":"15 3","pages":"98-104"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349319/pdf/ijppp0015-0098.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of physiology, pathophysiology and pharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: The goal of this study was to evaluate a low fixed-dose versus weight-based dosing strategy for four-factor prothrombin complex (4F-PCC) time to administration in intracranial hemorrhage (ICH) patients.
Methods: A retrospective analysis was conducted at a single rural Tertiary referral center in patients ≥18 years old on warfarin with ICH who received 4F-PCC. Continuous variables were summarized using mean (±95% CI) and compared using two-tailed tests; p values ≤0.05 were considered statistically significant.
Results: A total of 46 ICH patients were reversed using 4F-PCC (Fixed, n = 27 and Weight, n = 19). Baseline characteristics were equivalent. Total units of 4F-PCC (mean dose units 2525.1 versus 1623.3) and dose per kg were significantly reduced in the fixed-dose group. Total time from order to delivery was significantly reduced with the fixed-dose strategy (mean time 43.0 versus 29.0 minutes). Hospital length of stay (LOS), intensive care unit LOS, and mortality were equivalent with a similar mechanism. International Normalized Ratio (INR) reversal success (≤1.5) and total INR change was comparable with no difference in adverse thromboses between groups.
Conclusions: A fixed-dosed strategy reduced time to 4F-PCC administration for warfarin reversal in ICH, as compared to a weight-based strategy; with no increase in LOS, mortality, or need for additional dosing. This also resulted in significant cost savings.
目的:本研究的目的是评估低固定剂量与基于体重的给药策略对颅内出血(ICH)患者的四因素凝血酶原复合物(4F-PCC)给药时间。方法:回顾性分析在单一农村三级转诊中心对≥18岁华法林合并脑出血患者进行4F-PCC治疗。连续变量采用均值(±95% CI)汇总,采用双尾检验进行比较;P值≤0.05认为有统计学意义。结果:共有46例脑出血患者使用4F-PCC (Fixed, n = 27, Weight, n = 19)进行逆转。基线特征相同。固定剂量组4F-PCC总单位(平均剂量单位2525.1对1623.3)和每千克剂量显著降低。使用固定剂量策略,从订购到交付的总时间显著缩短(平均时间43.0分钟对29.0分钟)。住院时间(LOS)、重症监护病房LOS和死亡率具有相似的机制。国际标准化比值(INR)逆转成功率(≤1.5)和总INR变化具有可比性,两组间不良血栓发生率无差异。结论:与基于体重的策略相比,固定剂量策略减少了脑出血患者华法林逆转的4F-PCC给药时间;没有增加LOS、死亡率或需要额外剂量。这也大大节省了成本。